National Bank of Canada
MDNA

National Bank of Canada’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

National Bank of Canada’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-600
Closed -$272 – 2916
2023
Q2 		$272 Buy
+600
New +$371 ﹤0.01% 2656

Other funds holding MDNA

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return

National Bank of Canada's MDNA Position: Q3 2023 in Review

National Bank of Canada sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q3 2023, closing a stake of 600 shares — an estimated $272 sold.

National Bank of Canada first reported a position in MDNA in Q2 2023 and held it in 1 quarter. The position peaked at $272 in Q2 2023. 25 funds tracked by Wall St. Rank hold MDNA as of Q3 2023.

  • National Bank of Canada reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q3 2023 after selling out during the quarter.
  • National Bank of Canada sold 600 Medicenna Therapeutics Corp. Common Shares shares in Q3 2023, an estimated $272.
  • National Bank of Canada first reported a position in Medicenna Therapeutics Corp. Common Shares in Q2 2023 and held it in 1 quarter.
  • National Bank of Canada's Medicenna Therapeutics Corp. Common Shares position peaked at $272 in Q2 2023.
  • 25 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q3 2023.

Based on National Bank of Canada's 13F filing for Q3 2023, filed 10 Oct 2023.